Furthermore, combined inhibition of FGFR1–GLI1 with AZD + GANT61 inhibitors drastically decreased the migratory and invasive abilities of breast cancer cells, suggesting a novel mechanism to treat breast cancer patients. Here, GLI1 is linked to breast carcinoma.